Pfizer's hemophilia drug hits in phase 3, giving it a chance to leapfrog Novo Nordisk

Pfizer is looming large in Novo Nordisk’s rearview mirror. Weeks after seeing its rival for the hemophilia market stumble, Pfizer has reported phase 3 data that suggest its candidate is competitive and position it to file for approval in the coming months.